Deciphering ALDOB K87 Lactylation and Mitochondrial Dynamics in Pulmonary Hypertension

Study Background and Research Question

Pulmonary hypertension (PH) is a progressive and often fatal cardiopulmonary disorder characterized by elevated pulmonary arterial pressure, vascular remodeling, and right ventricular failure. Despite advances in vasodilator therapies, long-term outcomes remain poor as current treatments do not effectively reverse the underlying vascular remodeling driving disease progression (paper). Evidence increasingly points to profound metabolic reprogramming in pulmonary artery smooth muscle cells (PASMCs), including a shift from oxidative phosphorylation to aerobic glycolysis—the so-called Warburg effect. However, the molecular drivers linking altered metabolism to structural changes in pulmonary vasculature have been incompletely understood.

Key Innovation from the Reference Study

The recent study by Yi et al. (paper) provides a mechanistic leap by identifying lysine-87 (K87) lactylation of aldolase B (ALDOB) as a central regulator orchestrating mitochondrial fission and metabolic rewiring in PH. This work establishes a direct link between glycolytic flux, lactate-mediated protein modifications, and mitochondrial dynamics in PASMCs, highlighting the previously unappreciated role of nonhistone protein lactylation in pulmonary vascular pathology.

Methods and Experimental Design Insights

The investigators employed a multifaceted approach combining lactylomic profiling, in vitro cell biology, and in vivo rodent models of hypoxia-induced PH. Key experimental steps included:

• Lactylome sequencing of hypoxic PASMCs to map global and site-specific protein lactylation changes.
• Validation of ALDOB K87 lactylation in rodent PH tissues.
• Functional assays assessing PASMC proliferation, migration, and phenotypic switching in response to manipulation of ALDOB lactylation status.
• Genetic models including lactylation-deficient and lactylation-mimetic ALDOB mutants.
• Biochemical and imaging analyses of mitochondrial morphology and DRP1 recruitment.
• Pharmacological modulation of sirtuin 1 (SIRT1), identified as an ALDOB delactylase.

This design allowed the authors to trace the sequence from metabolic disturbance to molecular modification, cellular behavior, and, ultimately, in vivo pathophysiology.

Core Findings and Why They Matter

The study's central findings are as follows:

• ALDOB K87 lactylation is markedly elevated in hypoxic PASMCs and in rodent models of PH, correlating with disease severity (paper).
• ALDOB lactylation amplifies glycolytic flux, creating a feedforward loop of lactate accumulation and further protein lactylation.
• Lactylated ALDOB recruits DRP1 to mitochondria via sentrin/SUMO-specific peptidase 3 (SENP3)–mediated DRP1 deSUMOylation, promoting mitochondrial fission and fragmentation.
• This mitochondrial remodeling drives PASMC proliferation, migration, and phenotypic switching—hallmarks of vascular remodeling in PH (paper).
• SIRT1 acts as an ALDOB delactylase; its downregulation in PH sustains pathological lactylation.
• Pharmacological or genetic suppression of ALDOB lactylation reduces mitochondrial fission and mitigates PH progression in vivo, while mimetic mutants exacerbate disease phenotypes.

Collectively, these discoveries reveal a lactate–ALDOB–DRP1 axis that couples metabolic and mitochondrial signals to pathological smooth muscle cell growth, providing new molecular targets for intervention. The study also demonstrates the utility of protein lactylation profiling in uncovering disease mechanisms beyond classical histone modifications.

Comparison with Existing Internal Articles

Several recent reviews and protocols have discussed the intersection of metabolic regulation, mitochondrial dynamics, and smooth muscle cell proliferation in PH:

• ALDOB K87 Lactylation and Mitochondrial Dynamics in Pulmonary Hypertension offers a complementary synthesis, emphasizing the mechanistic link between ALDOB modification and DRP1-mediated fission, consistent with the reference paper.
• PDGF-BB, Murine Recombinant Protein: Molecular Pathways and Assay Precision discusses the value of PDGF-BB as a research tool in cell proliferation assays, contextualizing how mitogen-induced smooth muscle cell expansion can model PH-related processes.
• For technical optimization, Optimizing Cell Proliferation with Murine Recombinant PDGF-BB provides practical advice on achieving reproducible mitogenic responses—critical when modeling PASMC proliferation in studies like this.

The present reference study advances these frameworks by directly mapping the post-translational modification cascade driving mitochondrial and metabolic remodeling, rather than focusing solely on upstream mitogen signaling or phenotypic outcomes.

Protocol Parameters

• cell proliferation assay | ED50 < 2 ng/ml for murine BALB/c 3T3 cells | models mitogen-induced proliferation | establishes baseline mitogenic activity for research PDGF-BB | product_spec
• protein reconstitution | 0.1-1.0 mg/ml in sterile 100 mM acetic acid + 0.1% BSA | for bioactivity retention and assay reliability | ensures solubility and stability of recombinant PDGF-BB | product_spec
• PASMC proliferation/migration assays | variable, often 10–50 ng/ml PDGF-BB (recommend titration) | adapts to smooth muscle cell lines and primary cultures | supports modeling of PH-related remodeling in vitro | workflow_recommendation
• lactylome profiling | high-sensitivity mass spectrometry, custom antibody validation | maps site-specific protein lactylation | enables identification of nonhistone regulatory modifications | paper

Limitations and Transferability

While the reference study provides compelling mechanistic evidence, several limitations should be noted. First, most functional experiments were performed in rodent models and cultured PASMCs, which may not fully recapitulate the complexity of human PH. The translation of ALDOB lactylation-targeting interventions to clinical application remains to be demonstrated (paper). Second, while the lactate–ALDOB–DRP1 axis is well supported, potential crosstalk with other post-translational modifications or metabolic pathways warrants further investigation. Protocol recommendations for cell proliferation assays are generalizable to vascular research but may require adaptation for specific cell types or disease models (workflow_recommendation).

Research Support Resources

For researchers aiming to model smooth muscle cell proliferation and validate findings on metabolic or mitochondrial remodeling, standardized reagents are essential. The PDGF-BB, murine recombinant protein (SKU P1048) from APExBIO provides a high-purity, well-characterized mitogen suitable for cell-based assays examining PDGFR-α and PDGFR-β signaling, as referenced in both foundational and recent PH studies (product_spec). For optimal results, follow reconstitution and storage protocols as outlined by the manufacturer. This reagent supports reproducible research into vascular remodeling, metabolic reprogramming, and related mechanistic pathways in preclinical models.